The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | BrECADD vs Nivo-AVD in advanced Hodgkin lymphoma: selecting the right patients
Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, shares his perspective on the ongoing debate surrounding BrECADD and Nivo-AVD (nivolumab, doxorubicin, vinblastine, dacarbazine) for advanced-stage Hodgkin lymphoma. He discusses why BrECADD (brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone) may offer advantages for selected younger patients, particularly due to its shorter treatment duration and impressive long-term progression-free survival (PFS) data. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
